Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00484003
Other study ID # CASM981CZA01
Secondary ID
Status Completed
Phase Phase 4
First received June 7, 2007
Last updated February 13, 2008
Start date October 2004
Est. completion date December 2004

Study information

Verified date February 2008
Source Novartis
Contact n/a
Is FDA regulated No
Health authority South Africa: Medicines Control Council
Study type Interventional

Clinical Trial Summary

The study will evaluate the safety and effect of pimecrolimus cream 1% on quality of life of caregivers of South African children with mild to moderate atopic dermatitis (AD).


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date December 2004
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 2 Years to 12 Years
Eligibility Inclusion Criteria:

- Male or female

- Age =2 years =12 years of age

- Atopic dermatitis on sensitive skin areas only ( i.e. face , neck and flexures )

- Subjects in whom other treatment modalities are inadvisable according to the investigator's clinical opinion or have failed on other treatment modalities due to intolerance or inadequate response.

- Patients with a history of mild to moderate AD

- Subjects should present at visit 1 with a clear clinical diagnosis of mild to moderate AD.

- Subject's parents or legal guardian must have been informed of the study procedures and must have signed the Informed Consent form approved for the study prior to any study related procedures

Exclusion Criteria:

- Subjects who have active viral infections at the site(s) of treatment. In the presence of other dermatological infections, the use of appropriate antimicrobial agents should be instituted.

- Subjects who present with systemic malignancy or active lymphoproliferative diseases/disorders (e.g., lymphoma, neoplastic disease, chronic lymphoproliferation).

- Subjects who present with clinical conditions other than AD that can, in the opinion of the investigator, interfere with the evaluation

- Subjects who are receiving photo-therapy (e.g., PUVA, UVB) or immunosuppressive therapy (e.g., cyclosporine, FK-506 [tacrolimus]).

- Subjects who have used investigational drugs within 8 weeks prior to first application of study medication or intended use of other investigational drugs during the course of this study.

- Subjects who have used, or are using 0.03% or 0.1% tacrolimus ointment.

- Pimecrolimus cream 1% is contraindicated in subjects who have known or suspected hypersensitivity to pimecrolimus or any components of the cream

- Subjects not medically stable or subjects with any condition which, in the opinion of the investigator, should render the subject ineligible for the study.

- Pregnancy and lactation (if applicable)

- Pimecrolimus cream 1% should not be used during pregnancy or lactation

Other protocol-defined inclusion/exclusion criteria may apply

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Pimecrolimus cream 1%


Locations

Country Name City State
South Africa Investigative Sites Various Cities

Sponsors (1)

Lead Sponsor Collaborator
Novartis

Country where clinical trial is conducted

South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quality of Life assessment on scheduled visits at Day 1 (Baseline), Day 14 and Day 90 or day of early discontinuation visit.
Secondary Safety data will be collected by monitoring and recording all adverse events (AEs)and Serious Adverse Events(SAEs) throughout the duration of the trial.
See also
  Status Clinical Trial Phase
Completed NCT02381028 - Topical Treatment With Fresh Human Milk Versus Emollient on Atopic Eczema Spots in Young Children N/A
Recruiting NCT06230991 - A Pilot Study of Efficacy and Safety of SIM05 in Adults With Atopic Eczema N/A
Completed NCT05454722 - A Study to Evaluate Adex Gel in the Treatment of Atopic Eczema. N/A
Completed NCT01854580 - Evaluation of an Integrated Care Project
Completed NCT00555178 - Regulatory T Cells (Tregs) in Polymorphic Light Eruption N/A
Completed NCT00559546 - Montelukast as a Controller of Atopic Syndrome Phase 4
Completed NCT00224432 - Double-Blind, Parallel, Randomised Study to Investigate the Effect of Oral Probiotics in Infants With Atopic Dermatitis N/A
Active, not recruiting NCT03143504 - A Longitudinal Investigation of Skin Barrier Development From Birth and the Validation of Early Predictors of Atopic Eczema Risk: the Skin Testing for Atopic Eczema Risk (STAR) Study
Active, not recruiting NCT03409367 - A Community-based Assessment of Skin Care, Allergies, and Eczema N/A
Not yet recruiting NCT06453512 - A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema N/A
Completed NCT00826592 - Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis N/A
Completed NCT00576238 - Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser Phase 3
Active, not recruiting NCT05590585 - Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial Phase 4
Completed NCT01119313 - Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema Phase 2
Completed NCT00676884 - A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema Phase 2
Recruiting NCT03270566 - Softened Water for Eczema Prevention Pilot Trial N/A
Completed NCT02300701 - Role of Anti-IgE in Severe Childhood Eczema Phase 4
Completed NCT04114097 - The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover Phase 4
Completed NCT02915146 - Narrowband Ultraviolet B Versus Narrowband Ultraviolet B Plus Ultraviolet A1 for Atopic Eczema N/A
Recruiting NCT00771121 - Effect of Moisturizing Creams on Skin Barrier Function Phase 4